COMET
Comparison of Operative to Monitoring and Endocrine Therapy for Low-risk Ductal Carcinoma in Situ
- overview
- our role
- outcomes
The broad, long-term objective of the COMET trial is to provide high-quality evidence to help ductal carcinoma in situ (DCIS) patients and stakeholders understand the outcomes of treatment versus active surveillance. The COMET trial is funded by the Patient-Centered Outcomes Research Institute (PCORI), and conducted by the Alliance for Clinical Trials in Oncology, which is the largest adult cancer clinical trials network sponsored by the National Cancer Institute. The Principal Investigators are Dr. Shelley Hwang of Duke University, Dr. Ann Partridge of Dana-Farber Cancer Institute, and Dr. Alastair Thompson of MD Anderson.
CMTP manages a Stakeholder Advisory Board comprised of patients, patient advocates, payers, policymakers, regulators, clinicians, and researchers. Over the course of the project, stakeholders will provide input on study design, patient recruitment and outreach strategies, and mechanisms to reach underrepresented socioeconomic groups. They will also evaluate dissemination and translation strategies. The Stakeholder Advisory Board will ensure that clinical practice guidelines and quality measures reflect the needs and concerns of all stakeholders.
The COMET study will address high-priority evidence gaps related to the impact of guideline concordant care or active surveillance on patient-centered outcomes for DCIS. The research results will be used to promote informed, value-concordant care for patients and stakeholders affected by DCIS.